Delcath Systems, Inc. (NASDAQ:DCTH) was the recipient of a large growth in short interest during the month of August. As of August 15th, there was short interest totalling 59,973,525 shares, a growth of 41.4% from the July 31st total of 42,417,695 shares. Based on an average daily volume of 50,381,006 shares, the short-interest ratio is presently 1.2 days. Approximately 12.0% of the shares of the stock are sold short.

Hedge funds and other institutional investors have recently modified their holdings of the stock. Virtu KCG Holdings LLC boosted its position in shares of Delcath Systems by 72.4% in the second quarter. Virtu KCG Holdings LLC now owns 1,518,724 shares of the medical device company’s stock worth $299,000 after buying an additional 637,689 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of Delcath Systems by 207.0% in the second quarter. Vanguard Group Inc. now owns 1,285,679 shares of the medical device company’s stock worth $253,000 after buying an additional 866,838 shares in the last quarter. Finally, Renaissance Technologies LLC boosted its position in shares of Delcath Systems by 167.3% in the fourth quarter. Renaissance Technologies LLC now owns 160,128 shares of the medical device company’s stock worth $147,000 after buying an additional 100,214 shares in the last quarter. Hedge funds and other institutional investors own 0.56% of the company’s stock.

Delcath Systems (NASDAQ DCTH) opened at 0.1226 on Friday. Delcath Systems has a 12 month low of $0.02 and a 12 month high of $4.31. The company’s 50 day moving average price is $0.13 and its 200 day moving average price is $0.11. The firm’s market capitalization is $52.03 million.

ILLEGAL ACTIVITY WARNING: “Delcath Systems, Inc. (DCTH) Sees Large Growth in Short Interest” was first posted by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of United States and international trademark and copyright law. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2017/08/26/delcath-systems-inc-dcth-sees-large-growth-in-short-interest.html.

About Delcath Systems

Delcath Systems, Inc is a late-stage clinical development company with early commercial activity in Europe focused on cancers of the liver. The Company is a specialty pharmaceutical and medical device company developing its product, Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS).

Receive News & Ratings for Delcath Systems Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Delcath Systems Inc. and related companies with MarketBeat.com's FREE daily email newsletter.